SCHEMBL1121906

SCHEMBL1121906

O=S(=O)(CC1CN(C(c2ccccc2)c2ccccc2)C1)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
CACNA2D1 P54289 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNB1 Q02641 1/20 0.43
CACNA1C Q13936 1/20 0.43
MEN1 O00255 1/20 0.43
ATM Q13315 1/20 0.43
AGTR2 P50052 1/20 0.43
PKM P14618 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP14 P50281 1/20 0.41
CRBN Q96SW2 1/20 0.39
SCN9A Q15858 2/20 0.39
SCN7A Q01118 1/20 0.39
SCN5A Q14524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1121697 0.82 SCN9A (0.40) KMT2AMEN1ATMAGTR2OPRM1
SCHEMBL3296478 0.81 ALDH1A1 (0.47) KMT2ACACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL24809013 0.78 CYP2D6 (0.46) KMT2AMEN1OPRM1OPRD1SCN9A
SCHEMBL1130577 0.78 SLC6A9 (0.43) KMT2ACACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL5189063 0.77 MMP2 (0.40) AGTR2MMP2MMP9MMP14CRBN
SCHEMBL3296344 0.76 PSEN1 (0.38) KMT2ACRBNALDH1A1MAPTPSEN1
SCHEMBL1122123 0.76 CYP3A4 (0.43) KMT2ACACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL85392 0.75 OPRM1 (0.48) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL1121748 0.74 SCN9A (0.40) KMT2AMEN1ATMAGTR2OPRM1
SCHEMBL1121841 0.74 MMP2 (0.44) KMT2AMMP2MMP9MMP14CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
EP-1685100-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS Merck Sharp & Dohme Limited (GB) 2006-08-02 EP disclosed
WO-2005047246-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A KMT2A 1963/4885CACNA2D1 1315/4885CACNA1B 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.